| Clinivoy Infusion Care | |
|
4240 Latham St Ste A Riverside CA 92501-1741 | |
| (844) 243-7833 | |
| (949) 864-2320 |
| Full Name | Clinivoy Infusion Care |
|---|---|
| Speciality | General Practice |
| Location | 4240 Latham St Ste A, Riverside, California |
| Authorized Official Name and Position | Genevieve Benjamin (CEO) |
| Authorized Official Contact | 9497837009 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Clinivoy Infusion Care 16782 Von Karman Ave Ste 12 Irvine CA 92606-2417 Ph: (858) 314-9222 | Clinivoy Infusion Care 4240 Latham St Ste A Riverside CA 92501-1741 Ph: (844) 243-7833 |
| NPI Number | 1073240529 |
|---|---|
| Provider Enumeration Date | 08/04/2022 |
| Last Update Date | 03/25/2024 |
| Medicare PECOS PAC ID | 2365828720 |
|---|---|
| Medicare Enrollment ID | O20221007002620 |
News Archive
On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, "Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials" to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.
A new degree designed to equip doctors and scientists with the expertise needed to investigate deaths resulting from acts of genocide, terrorism, natural disasters such as Tsunami, transport accidents and drug abuse will be launched this week at an international Forensic Science conference in Hong Kong.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073240529 | NPI | - | NPPES |
| Provider Name | Bachir K Younes |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1184661571 PECOS PAC ID: 8123024460 Enrollment ID: I20061010000704 |
News Archive
On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, "Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials" to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.
A new degree designed to equip doctors and scientists with the expertise needed to investigate deaths resulting from acts of genocide, terrorism, natural disasters such as Tsunami, transport accidents and drug abuse will be launched this week at an international Forensic Science conference in Hong Kong.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 1 days ago
| Provider Name | Mona M Ghobrial |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033319173 PECOS PAC ID: 8628122249 Enrollment ID: I20110913000769 |
News Archive
On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, "Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials" to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.
A new degree designed to equip doctors and scientists with the expertise needed to investigate deaths resulting from acts of genocide, terrorism, natural disasters such as Tsunami, transport accidents and drug abuse will be launched this week at an international Forensic Science conference in Hong Kong.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 1 days ago
| Provider Name | Andrea Flores Leal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629713839 PECOS PAC ID: 5294196903 Enrollment ID: I20230727002626 |
News Archive
On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, "Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials" to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.
A new degree designed to equip doctors and scientists with the expertise needed to investigate deaths resulting from acts of genocide, terrorism, natural disasters such as Tsunami, transport accidents and drug abuse will be launched this week at an international Forensic Science conference in Hong Kong.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 1 days ago
| Provider Name | Desiree Medina |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386213361 PECOS PAC ID: 5395130934 Enrollment ID: I20231108002864 |
News Archive
On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, "Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials" to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.
A new degree designed to equip doctors and scientists with the expertise needed to investigate deaths resulting from acts of genocide, terrorism, natural disasters such as Tsunami, transport accidents and drug abuse will be launched this week at an international Forensic Science conference in Hong Kong.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 1 days ago
News Archive
On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, "Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials" to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.
A new degree designed to equip doctors and scientists with the expertise needed to investigate deaths resulting from acts of genocide, terrorism, natural disasters such as Tsunami, transport accidents and drug abuse will be launched this week at an international Forensic Science conference in Hong Kong.
A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.
› Verified 1 days ago
Innovative Medical Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4500 Brockton Ave Ste 305, Riverside, CA 92501 Phone: 206-445-9978 Fax: 858-280-3279 | |
Pulmonary Partners Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5790 Magnolia Ave, Suite 201, Riverside, CA 92506 Phone: 951-368-0427 Fax: 951-368-0429 | |
Lyn M Pintelon D.o. Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8990 Garfield St, Ste.6, Riverside, CA 92503 Phone: 951-358-0784 Fax: 951-354-7583 | |
Precision Spinal Care Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4224 Cedar Pine Ct, Riverside, CA 92505 Phone: 909-648-0377 | |
Parkview Medical Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3722 Tibbetts St, Riverside, CA 92506 Phone: 951-784-3770 | |
Orangecrest Medical Group, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4646 Brockton Ave Ste 203, Riverside, CA 92506 Phone: 951-774-2881 Fax: 951-774-2846 | |
Harmony Health Solutions Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5750 Division St Ste 208, Riverside, CA 92506 Phone: 310-560-9292 |